Skip to content
StackItSmart
BHuman cohort / observational

L-Carnitine (Injectable)

Levocarnitine

L-Carnitine (levocarnitine) is a naturally occurring quaternary amine that shuttles long-chain fatty acids into mitochondria for beta-oxidation. The injectable (chiefly intravenous) form is an FDA-approved prescription drug for primary systemic carnitine deficiency and for carnitine depletion in end-stage renal disease patients on hemodialysis; these are its only evidence-supported uses. It is often marketed to physique/endurance users as a fat-oxidation or "metabolic support" ancillary, but there is no adequate human evidence that injectable carnitine improves body composition, strength, or performance in people who are not carnitine-deficient. The main risks are that chronic supplementation is metabolized by gut bacteria to trimethylamine-N-oxide (TMAO), a metabolite linked in human cohort and animal data to accelerated atherosclerosis and major adverse cardiac events; a strong fishy body/breath odor from trimethylamine; GI upset; and the fact that only pharmaceutical-grade L-carnitine (never the racemic D,L form) should ever be given, because the D-isomer can cause a myasthenia-like muscle weakness. Injectable use bypasses first-pass metabolism, giving far higher blood levels than oral dosing, and non-sterile self-injection carries the usual infection/abscess/embolism risks of any injection. This is not a hormone and does not suppress the HPTA. Use of the injectable outside a supervised deficiency/dialysis context is not supported by primary human data.

Clinical readoutAncillary · metabolic-support
Hepatic strainLow
CardiovascularNone
HPTA suppressionNone
Half-life
17.5 h
Route
Injectable is given int…
Evidence
B
Active
Plasma levels fall over…
17.5 h35 h2.2 d2.9 d3.6 d
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Multicompartment. After IV dosing the plasma disposition is rapid initially, with a terminal elimination half-life on the order of ~15-20 hours; the slowest-equilibrating pool (skeletal and cardiac muscle) turns over far more slowly, so full tissue repletion takes repeated dosing over weeks.
Pharmacology

Mechanism of action

L-Carnitine is the physiologically active isomer that binds long-chain acyl groups via carnitine palmitoyltransferase I/II and the carnitine-acylcarnitine translocase, transporting activated fatty acids across the inner mitochondrial membrane for beta-oxidation and ATP production. It also buffers the mitochondrial acyl-CoA/CoA ratio, esterifying and exporting accumulated acyl groups (including toxic metabolites), which underlies its use in organic acidurias and valproate-induced hyperammonemia. Cellular uptake into muscle, heart, and kidney is carrier-mediated, principally by the OCTN2 (SLC22A5) transporter; loss-of-function OCTN2 variants cause primary carnitine transporter deficiency. Injectable/IV dosing raises plasma and, more slowly, tissue carnitine, correcting deficiency states; it does not create a supraphysiologic fat-burning effect in carnitine-replete people. A separate, unwanted "mechanism" is microbiome-dependent: gut bacteria convert dietary and supplemental carnitine to trimethylamine, which the liver oxidizes to the pro-atherogenic metabolite TMAO.
Kinetics

Pharmacokinetics

Half-life

Multicompartment. After IV dosing the plasma disposition is rapid initially, with a terminal elimination half-life on the order of ~15-20 hours; the slowest-equilibrating pool (skeletal and cardiac muscle) turns over far more slowly, so full tissue repletion takes repeated dosing over weeks.

Active duration

Plasma levels fall over hours; clinically the drug is dosed intermittently (e.g., after each hemodialysis session, ~3x/week) reflecting the need for repeated administration to sustain tissue carnitine rather than a single sustained effect. Not a washout/detection-evasion parameter.

Route

Injectable is given intravenously (standard in hemodialysis, as a slow IV bolus after the session); IM/SC use is uncommon. Bypasses the poor, saturable oral absorption (oral absolute bioavailability only ~5-18% at 1-6 g doses), producing much higher blood concentrations than oral supplements.

Metabolism & clearance

Not extensively hepatically metabolized as a drug; eliminated mainly by renal excretion. Under baseline conditions renal clearance is low (~1-3 mL/min) due to extensive (98-99%) tubular reabsorption, but clearance rises toward GFR after high IV doses once the tubular reabsorption threshold (~40-60 micromol/L) is exceeded. In dialysis patients, carnitine is freely removed across the dialyzer, the rationale for post-dialysis dosing. A microbiome-dependent fraction is converted to trimethylamine and hepatically oxidized to TMAO.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Corrects primary systemic (OCTN2/carnitine transporter) deficiency and secondary deficiency states (e.g., organic acidurias, some drug-induced depletion), improving associated hypotonia, muscle weakness, and cardiomyopathy in deficient patients.
  • Restores carnitine levels that fall progressively during long-term hemodialysis (levels drop ~11% over the first year; ~30% of untreated incident dialysis patients become deficient).
  • Facilitates fatty-acid beta-oxidation and buffers mitochondrial acyl-CoA, supporting clearance of toxic acyl metabolites (basis for use in valproate-induced hyperammonemic encephalopathy).
  • In an acute-MI meta-analysis, associated with reduced all-cause mortality, ventricular arrhythmias, and angina versus placebo/control - a benefit signal that predates modern reperfusion care and has not been confirmed in large modern trials.
  • No demonstrated benefit for erythropoietin (rHuEPO) resistance/anemia in incident hemodialysis patients (CARNIDIAL RCT was negative), and no adequate human evidence of fat-loss, muscle-gain, or performance benefit in carnitine-replete individuals.
Safety

Adverse effects by system

Cardiovascular

Two opposing signals. In an acute-MI meta-analysis L-carnitine was associated with lower mortality and fewer ventricular arrhythmias. However, chronic carnitine intake generates TMAO, which in a large human cohort (n=2,595) predicted increased prevalent CVD and incident MI/stroke/death (only among those with high TMAO), and accelerated atherosclerosis in mice. Net cardiovascular effect of chronic non-deficiency supplementation is uncertain and potentially harmful.

Hepatic

No signal for direct hepatotoxicity; carnitine is used adjunctively to counter valproate-induced hepatic/mitochondrial toxicity and hyperammonemia rather than causing liver injury.

Endocrine / HPTA

Not a hormone; no known effect on the hypothalamic-pituitary-gonadal axis or endogenous testosterone. No adequate data suggesting endocrine disruption.

Reproductive

No adequate human data on adverse reproductive effects of the injectable form; some oral-carnitine fertility studies exist but do not establish injectable reproductive harm or benefit.

Neuropsychiatric

No consistent psychiatric adverse effect established. Product labeling and case literature note seizures have occurred in patients receiving carnitine, chiefly those with a pre-existing seizure disorder; conversely carnitine is used to treat valproate-induced encephalopathy. Neuro/psychiatric data specific to the injectable are limited - no adequate human data for a defined psychiatric risk.

Renal

No direct nephrotoxicity described; the drug is renally cleared and is specifically used in ESRD/hemodialysis. In dialysis populations it is generally well tolerated when given post-session. Accumulation in severe renal impairment is a monitoring consideration.

Hematologic

No adverse hematologic effect established. Studied for (and failed to improve) EPO-resistant anemia in dialysis patients; it did not worsen hematologic parameters.

Dermatologic

Injection-site reactions are possible with any parenteral drug; a characteristic strong fishy body/skin odor from trimethylamine can occur with higher intakes. No systematic dermatologic toxicity data.

Recovery

HPTA suppression & recovery

Suppression: None expected - L-carnitine is not a hormone or SERM and has no known mechanism to suppress the hypothalamic-pituitary-gonadal axis.

No HPTA recovery protocol is applicable to carnitine itself. Nothing here should be construed as endorsing any SERM protocol; if carnitine is being used alongside anabolic-androgenic steroids that do suppress the axis, any post-cycle or recovery management must be individualized and directed by an endocrinologist rather than self-managed.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Plasma total and free carnitine and acylcarnitine profile (to confirm genuine deficiency before use and to guide dosing)Renal function (eGFR/creatinine), especially in CKD/ESRDBasic metabolic panel and ammonia if used in the valproate/hyperammonemia contextConsider fasting lipids and, where available, TMAO given the atherosclerosis signal with chronic useBlood pressure and cardiac symptom review in patients with cardiovascular disease

Cadence: Establish a baseline carnitine/renal panel before starting; recheck carnitine status and renal function periodically (e.g., every few months) during chronic dosing and after any dose change; in dialysis patients follow the treating nephrology team's schedule.

Warning signs — seek care
  • New or worsening seizures
  • New or worsening muscle weakness (raises concern for a D,L-carnitine product)
  • Persistent fishy body/breath odor with GI intolerance
  • Signs of injection-site or systemic infection (redness, swelling, fever) with self-injection
  • Chest pain, palpitations, or other cardiac symptoms - stop and seek care
  • Severe or persistent nausea, vomiting, abdominal cramps, or diarrhea
Do not use if

Contraindications

  • Use of racemic D,L-carnitine (or the D-isomer) is contraindicated - it can cause a myasthenia-like muscle weakness; only pharmaceutical L-carnitine/levocarnitine should be used.
  • Known hypersensitivity to the product.
  • Caution in patients with a seizure disorder - new-onset or increased seizure frequency has been reported in patients on carnitine (per product labeling).
  • Relative caution with chronic high-dose use in established atherosclerotic cardiovascular disease given the TMAO signal.
  • Severe renal impairment without dialysis: renally cleared drug; dosing and accumulation require clinician oversight.
  • Not a substitute for medically supervised management of any deficiency state - injectable use should be under a clinician.
Combinations

Interaction profile

  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • Injectable carnitine has proven value only for genuine carnitine deficiency and dialysis-related depletion - confirm deficiency with a plasma carnitine/acylcarnitine panel and a clinician before considering it; do not use it for fat loss or performance, where no adequate human data support benefit.
  • Use only pharmaceutical-grade L-carnitine/levocarnitine; never racemic D,L-carnitine, which can cause a myasthenia-like muscle weakness.
  • Be aware chronic supplementation raises TMAO, associated with atherosclerosis and adverse cardiac events in human data - a reason to avoid indefinite non-medical use, especially with existing cardiovascular disease.
  • Stop and seek medical care for new or worsening seizures, new muscle weakness, chest pain/palpitations, or signs of injection-site or systemic infection.
  • Non-sterile or unsupervised self-injection carries infection, abscess, and embolism risks independent of the drug; sterile technique and clinician oversight are essential.
  • This monograph is harm-reduction information, not medical advice or a dosing recommendation; deficiency treatment, dosing, and monitoring should be directed by a physician (nephrologist/metabolic specialist), and any hormonal-recovery questions by an endocrinologist.
Evidence

Citations (9)

Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.

  1. 01

    L-carnitine facilitates transport of fatty acids into mitochondria for beta-oxidation; used clinically for primary and secondary carnitine deficiency and related conditions.

    ReviewPMID 36632072 ↗

  2. 02

    Injectable/IV L-carnitine bypasses poor oral bioavailability (oral absolute bioavailability only ~5-18% at 1-6 g); after IV dosing initial distribution volume is ~0.2-0.3 L/kg, elimination is mainly renal with extensive (98-99%) tubular reabsorption and low baseline renal clearance (~1-3 mL/min) rising toward GFR at high doses; slowest-equilibrating pool is skeletal and cardiac muscle.

    ReviewPMID 12908852 ↗

  3. 03

    Gut-microbiota metabolism of L-carnitine produces TMAO; plasma L-carnitine predicted increased prevalent CVD and incident MI/stroke/death in a human cohort (n=2,595) among those with high TMAO, and chronic carnitine accelerated atherosclerosis in mice.

    CohortPMID 23563705 ↗

  4. 04

    In acute myocardial infarction, L-carnitine was associated with 27% lower all-cause mortality, 65% fewer ventricular arrhythmias, and 40% less angina versus placebo/control (meta-analysis of 13 trials, n=3,629).

    Meta-analysisPMID 23597877 ↗

  5. 05

    Carnitine levels fall progressively during hemodialysis (~11% over the first year) with ~30% of untreated incident patients becoming deficient; IV L-carnitine 1 g after each dialysis session raised carnitine levels but did NOT improve rHuEPO resistance (CARNIDIAL double-blind RCT).

    RCTPMID 22935844 ↗

  6. 06

    IV L-carnitine (10 mg/kg after each hemodialysis session) did not improve leukocyte phagocytic function/viability or clinical/biochemical dialysis parameters in a double-blind RCT.

    RCTPMID 10516349 ↗

  7. 07

    Levocarnitine is used to treat valproic-acid-induced hyperammonemic encephalopathy by restoring the cofactor needed for valproate metabolism and ammonia elimination; evidence is retrospective/case-based and it was generally safe with no reported carnitine-related adverse events.

    ReviewPMID 22180549 ↗

  8. 08

    Case report: carnitine 1 g/day reversed valproate-associated hyperammonemia and improved seizure control, illustrating carnitine's role in ammonia elimination.

    Case reportPMID 28425821 ↗

  9. 09

    Primary carnitine transporter deficiency is caused by loss-of-function variants in OCTN2 (SLC22A5); the disorder is potentially lethal but actionable, with cellular carnitine uptake being carrier-mediated.

    PreclinicalPMID 36343260 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice